The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Amphotericin B: 30 Years of Clinical Experience
Abstract
Amphotericin B, the first commercially significant antifungal drug, has been available for more than 30 years. This polyene macrolide antifungal agent continues to play a major role in the treatment of systemic fungal infections, despite the introduction of newer agents such as the azoles. Given the proved efficacy of amphotericin B--and the increasing number of indications for antifungal agents--an extensive review of this drug is warranted. This paper discusses the clinical uses of amphotericin B, including its application in AIDS-related fungal infections, in neutropenic cancer patients who are persistently febrile, and in infections of the central nervous system, lung, peritoneum, genitourinary system, eye, and skin. The paper also reviews the drug's adverse reactions, with a discussion of administration techniques that may reduce these reactions, and its spectrum of activity, pharmacokinetics, and dosage and administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Self-citationPizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Cryptococcosis in the Acquired Immunodeficiency Syndrome
KOVACS, J. A., KOVACS, A. A., POLIS, M., WRIGHT, W. C., GILL, V. J., TUAZON, C. U., GELMANN, E. P., LANE, H. C., LONGFIELD, R., OVERTURF, G., et al. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-533 · Cited by 621
Azole antifungal agents: Emphasis on new triazoles
Saag, M. S., & Dismukes, W. E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.1.1 · Cited by 474
EDWARDS, J. E., LEHRER, R. I., STIEHM, E. R., FISCHER, T. J., & YOUNG, L. S. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-1-91 · Cited by 384
Fungal infections in patients with acute leukemia
Degregorio, M. W., Lee, W. M. F., Linker, C. A., Jacobs, R. A., & A. Ries, C. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90334-5 · Cited by 354
Strategies in the Treatment of Systemic Fungal Infections
Medoff, G., & Kobayashi, G. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198001173020304 · Cited by 342
Nephrotoxicity of Amphotericin B
Butler, W. T., BENNETT, J. E., ALLING, D. W., WERTLAKE, P. T., UTZ, J. P., & HILL, G. J. (1964) · Annals of Internal Medicine · doi:10.7326/0003-4819-61-2-175 · Cited by 326
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
“Treatment with AmB desoxycholate is limited by poor toleration and nephrotoxicity [7, 8].”
BackgroundAmphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Targeted Delivery of Amphotericin B to Cells by Using Functionalized Carbon Nanotubes
Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J., Gennaro, R., Prato, M., & Bianco, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501613 · Cited by 644
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Antifungal agents: chemotherapeutic targets and immunologic strategies
Georgopapadakou, N. H., & Walsh, T. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.279 · Cited by 498
Immunological Consequences of Intestinal Fungal Dysbiosis
Wheeler, M. L., Limon, J. J., Bar, A. S., Leal, C. A., Gargus, M., Tang, J., Brown, J., Funari, V. A., Wang, H. L., Crother, T. R., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.003 · Cited by 422
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Amphotericin B: new life for an old drug
Hartsel, S., & Bolard, J. (1996) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)01012-7 · Cited by 347
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues
Aher, N. G., Pore, V. S., Mishra, N. N., Kumar, A., Shukla, P. K., Sharma, A., & Bhat, M. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.026 · Cited by 328
Discovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J., Meinz, M., Thompson, J., Curotto, J., Dreikorn, S., Rosenbach, M., Douglas, C., Abruzzo, G., Flattery, A., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 326
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“penetrate certain niches of the body, dose-limiting renal toxicity, or the underlying disease of the patient [6,7,9].”
BackgroundPharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Carrier effects on biological activity of amphotericin B
Brajtburg, J., & Bolard, J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.512 · Cited by 310
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296
Anaissie, E. J., Darouiche, R. O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L. O., Williams, T., Kontoyiannis, D. P., Karl, C. L., & Bodey, G. P. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.5.964 · Cited by 278
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Overview of the lipid formulations of amphotericin B
Dupont, B. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.31 · Cited by 260
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1360-1367.2001 · Cited by 258
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225
Agarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204
Winston, D. J., Hathorn, J. W., Schuster, M. G., Schiller, G. J., & Territo, M. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00457-x · Cited by 189
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150
Kuipers, M. E., de Vries, H. G., Eikelboom, M. C., Meijer, D. K. F., & Swart, P. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2635 · Cited by 148
Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model
Zarif, L., Graybill, J. R., Perlin, D., Najvar, L., Bocanegra, R., & Mannino, R. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1463-1469.2000 · Cited by 122
Viscoli, C., Castagnola, E., Van Lint, M. T., Moroni, C., Garaventa, A., Rossi, M. R., Fanci, R., Menichetti, F., Caselli, D., Giacchino, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00619-2 · Cited by 122
Marchetti, O., Entenza, J. M., Sanglard, D., Bille, J., Glauser, M. P., & Moreillon, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2932-2938.2000 · Cited by 113
Espinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1828-1835.2001 · Cited by 83
Xu, Julin, G., Yuanjie, Z., Hai, W., Qiushi, R., & Jianghan, C. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17503 · Cited by 69
Antifungal Spectrum, In Vivo Efficacy, and Structure–Activity Relationship of Ilicicolin H
Singh, S. B., Liu, W., Li, X., Chen, T., Shafiee, A., Card, D., Abruzzo, G., Flattery, A., Gill, C., Thompson, J. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300173e · Cited by 63
LY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability
Green, L. J., Marder, P., Mann, L. L., Chio, L.-C., & Current, W. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.830 · Cited by 57
Sinnollareddy, M., Peake, S. L., Roberts, M. S., Lipman, J., & Roberts, J. A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.013 · Cited by 56
Purulent Pericarditis Caused by Candida Species: Case Report and Review
Schrank, J. H., & Dooley, D. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.182 · Cited by 48
Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
Cantón, E., Pemán, J., Sastre, M., Romero, M., & Espinel-Ingroff, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00524-06 · Cited by 37
Acute Renal Failure in HIV-Infected Patients: A Brief Review of Common Causes
Perazella, M. A. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40779-7 · Cited by 35
Singh, S. B., Liu, W., Li, X., Chen, T., Shafiee, A., Dreikorn, S., Hornak, V., Meinz, M., & Onishi, J. C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.023 · Cited by 33
Aspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Metadata
- Authors
- Gallis, H. A., Drew, R. H., & Pickard, W. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-03-01
- Volume
- 12
- Issue
- 2
- Pages
- 308-329
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1998840608
- Cited by
- 1,009
- References
- 116
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.